Signalling by Transforming Growth Factor Beta Isoforms in Wound Healing and Tissue Regeneration

Overview

Journal J Dev Biol

Specialty Biology

Date 2018 Apr 5

PMID 29615587

Citations 74

Authors

Richard W D Gilbert

Matthew K Vickaryous

Alicia M Viloria-Petit

Affiliations

Soon will be listed here.

Abstract

Transforming growth factor beta (TGFβ) signalling is essential for wound healing, including both non-specific scar formation and tissue-specific regeneration. Specific TGFβ isoforms and downstream mediators of canonical and non-canonical signalling play different roles in each of these processes. Here we review the role of TGFβ signalling during tissue repair, with a particular focus on the prototypic isoforms TGFβ1, TGFβ2, and TGFβ3. We begin by introducing TGFβ signalling and then discuss the role of these growth factors and their key downstream signalling mediators in determining the balance between scar formation and tissue regeneration. Next we discuss examples of the pleiotropic roles of TGFβ ligands during cutaneous wound healing and blastema-mediated regeneration, and how inhibition of the canonical signalling pathway (using small molecule inhibitors) blocks regeneration. Finally, we review various TGFβ-targeting therapeutic strategies that hold promise for enhancing tissue repair.

Citing Articles

Lovastatin and Resveratrol Synergistically Improve Wound Healing and Inhibit Bacterial Growth.

AlJunaydil N, Lambarte R, Sumague T, Alghamdi O, Niazy A Int J Mol Sci. 2025; 26(2).

PMID: 39859566 PMC: 11766293. DOI: 10.3390/ijms26020851.

Elevating Dermatology Beyond Aesthetics: Perinatal-Derived Advancements for Rejuvenation, Alopecia Strategies, Scar Therapies, and Progressive Wound Healing.

Khalilzad M, Mohammadi J, Amirsaadat S, Najafi S, Zare S, Nilforoushzadeh M Stem Cell Rev Rep. 2025; .

PMID: 39804520 DOI: 10.1007/s12015-024-10835-y.

Wildfire-relevant woodsmoke and extracellular vesicles (EVs): Alterations in EV proteomic signatures involved in extracellular matrix degradation and tissue injury in airway organotypic models.

Vitucci E, Carberry C, Payton A, Herring L, Mordant A, Kim Y Environ Res. 2024; 264(Pt 2):120395.

PMID: 39571711 PMC: 11694228. DOI: 10.1016/j.envres.2024.120395.

The mechanics of the retina: Müller glia role on retinal extracellular matrix and modelling.

Prieto-Lopez L, Pereiro X, Vecino E Front Med (Lausanne). 2024; 11:1393057.

PMID: 39296899 PMC: 11410058. DOI: 10.3389/fmed.2024.1393057.

Regenerative Therapy for Corneal Scarring Disorders.

Chandran C, Santra M, Rubin E, Geary M, Yam G Biomedicines. 2024; 12(3).

PMID: 38540264 PMC: 10967722. DOI: 10.3390/biomedicines12030649.

References

Antsiferova M, Werner S . The bright and the dark sides of activin in wound healing and cancer. J Cell Sci. 2012; 125(Pt 17):3929-37. DOI: 10.1242/jcs.094789. View

Shakir S, MacIsaac Z, Naran S, Smith D, Bykowski M, Cray J . Transforming growth factor beta 1 augments calvarial defect healing and promotes suture regeneration. Tissue Eng Part A. 2014; 21(5-6):939-47. PMC: 4356478. DOI: 10.1089/ten.TEA.2014.0189. View

Reed N, Jo H, Chen C, Tsujino K, Arnold T, DeGrado W . The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015; 7(288):288ra79. PMC: 4461057. DOI: 10.1126/scitranslmed.aaa5094. View

Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N . The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008; 10(10):1199-207. DOI: 10.1038/ncb1780. View

Mead A, Wong T, Cordeiro M, Anderson I, Khaw P . Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003; 44(8):3394-401. DOI: 10.1167/iovs.02-0978. View

Bilandzic M, Stenvers K . Reprint of: Betaglycan: a multifunctional accessory. Mol Cell Endocrinol. 2012; 359(1-2):13-22. DOI: 10.1016/j.mce.2012.03.020. View

Akhurst R, Hata A . Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012; 11(10):790-811. PMC: 3520610. DOI: 10.1038/nrd3810. View

Singer A, Clark R . Cutaneous wound healing. N Engl J Med. 1999; 341(10):738-46. DOI: 10.1056/NEJM199909023411006. View

Dupont S . Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. Exp Cell Res. 2015; 343(1):42-53. DOI: 10.1016/j.yexcr.2015.10.034. View

10.

Monaghan J, Athippozhy A, Seifert A, Putta S, Stromberg A, Maden M . Gene expression patterns specific to the regenerating limb of the Mexican axolotl. Biol Open. 2012; 1(10):937-48. PMC: 3507169. DOI: 10.1242/bio.20121594. View

11.

Corr D, Gallant-Behm C, Shrive N, Hart D . Biomechanical behavior of scar tissue and uninjured skin in a porcine model. Wound Repair Regen. 2009; 17(2):250-9. DOI: 10.1111/j.1524-475X.2009.00463.x. View

12.

Opalenik S, Davidson J . Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J. 2005; 19(11):1561-3. DOI: 10.1096/fj.04-2978fje. View

13.

Seifert A, Kiama S, Seifert M, Goheen J, Palmer T, Maden M . Skin shedding and tissue regeneration in African spiny mice (Acomys). Nature. 2012; 489(7417):561-5. PMC: 3480082. DOI: 10.1038/nature11499. View

14.

Hawinkels L, Ten Dijke P . Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors. 2011; 29(4):140-52. DOI: 10.3109/08977194.2011.595411. View

15.

Arora P, Narani N, McCulloch C . The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. Am J Pathol. 1999; 154(3):871-82. PMC: 1866402. DOI: 10.1016/s0002-9440(10)65334-5. View

16.

So K, McGrouther D, Bush J, Durani P, Taylor L, Skotny G . Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg. 2011; 128(1):163-172. DOI: 10.1097/PRS.0b013e318217429b. View

17.

Brandes M, Mai U, Ohura K, Wahl S . Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol. 1991; 147(5):1600-6. View

18.

Inman G, Nicolas F, Callahan J, Harling J, Gaster L, Reith A . SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002; 62(1):65-74. DOI: 10.1124/mol.62.1.65. View

19.

Tang W, Ling G, Sun L, Liu F . Smad anchor for receptor activation (SARA) in TGF-beta signaling. Front Biosci (Elite Ed). 2010; 2(3):857-60. DOI: 10.2741/e147. View

20.

Wu L, Siddiqui A, Morris D, Cox D, Roth S, Mustoe T . Transforming growth factor beta 3 (TGF beta 3) accelerates wound healing without alteration of scar prominence. Histologic and competitive reverse-transcription-polymerase chain reaction studies. Arch Surg. 1997; 132(7):753-60. DOI: 10.1001/archsurg.1997.01430310067014. View